TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects and/or parent(s)/legally acceptable representative must be considered willing and able to sign consent, and complete daily seizure diaries and monitor seizure frequency.~* Male and female epilepsy subjects, 4 to 16 years of age inclusive on the date of the Screening Visit.~* Diagnosis of epilepsy with partial onset seizures classified as simple partial, complex partial or partial becoming secondarily generalized, according to the International League Against Epilepsy (ILAE) Diagnosis criteria.~* Must have a partial onset seizure frequency of at least 3 seizures per 28 day period prior to screening. Must have a partial onset seizure frequency of at least 6 seizures and no continuous 4 week seizure free period during the 8 week baseline phase prior to randomization.~* Currently receiving a stable dose of 1 to 3 antiepileptic drugs (stable within 28 days prior to screening).~Exclusion Criteria:~* Primary generalized seizures (including in the setting of co-existing partial onset seizures) which include, for example: Clonic, tonic and clonic-tonic seizures (note that partial onset seizures that become secondarily generalized are not exclusionary); Absence seizures; Infantile spasms; Myoclonic, myoclonic atonic, myoclonic tonic seizures.~* Lennox Gastaut syndrome, Benign Epilepsy with Centrotemporal Spikes (BECTS) and Dravet syndrome.~* A current diagnosis of febrile seizures, or seizures related to an ongoing acute medical illness. Any febrile seizures within 1 year of screening.~* Status epilepticus within 1 year prior to screening.~* Seizures related to drugs, alcohol, or acute medical illness.~* Any change in AED regimen (type of medication or dose) within 28 days of the Screening Visit or during the Baseline Phase.~* Progressive structural CNS lesion or a progressive encephalopathy.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Pregabalin Level 1 (max 150 mg/day) (Type: EXPERIMENTAL): None
- Pregabalin Level 2 (max 600 mg day) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Thalidomide in Treating Crohn's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~A CDAI score greater than 150 at baseline was required for inclusion .(1) steroid-dependent: unable to reduce steroids below the equivalent of prednisone 10 mg/day (or budesonide below 3 mg/day) within 3 months of starting steroids, or who have a relapse within 3 months of stopping steroids.(2) thiopurines-non-responsive: active disease or clinical relapse despite administration of azathioprine (1.5-2 mg per kg per day) or 6-mercaptopurine (0.75-1.5 mg per kg per day) for 4 months. (3) thiopurines- intolerant: intolerance to or adverse events of thiopurines.~The exclusion criteria were (1) isolated L4 CD; (2) disease including symptomatic stenosis of intestine or abdominal abscess requiring immediate surgery; (3) Current or past history of malignancy or organ transplantation; (4) Serious infections within 3 months; (5) Previous history of neuropathy or symptoms of neuropathy or abnormal electromyography prior to thalidomide; (6) infliximab treatment in the previous 8 weeks; (7) progressive or uncontrolled renal, hepatic, hematological, pulmonary and cardiac disease and（8）ongoing pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Thalidomide (Type: EXPERIMENTAL): Thalidomide was administered at a daily dose of 50 mg to the patients. Dosage adjustment of thalidomide from 25mg daily to 100mg daily was tailored individually according to patients' tolerance to thalidomide. To minimize the sedative effect of thalidomide, the investigators recommended patients take a single dose of the study drug in the evening before bedtime.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~The prospective participant must meet, at least, all of the criteria below to be eligible for study participation. The participant:~* Is a minimum age of 18 years (adults) or 50 years (aging participants);~* Is male or female;~* Has confirmed infection with HIV-1 (positive HIV test according to appropriate standard practice);~* Has commenced antiretroviral treatment with Raltegravir according to the recommendations made in the Summary of Product Characteristics at the time of enrollment on the study, or a maximum 6 months prior to enrollment on the study;~* Has any cluster of differentiation (CD4) cell (specialized white blood cell) count upon enrollment on the study.~Exclusion criteria~If the prospective participant meets any of the criteria below (among others determined by the study staff) they will NOT be eligible for study participation. The participant:~* For which Raltegravir, or its ingredients, are contraindicated;~* Has intolerance to Raltegravir, or its ingredients;~* If female, is pregnant, breastfeeding, or is planning a pregnancy or egg donation during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Overall Participants (Type: None): HIV-1 infected participants received raltegravir 400 mg tablet orally twice daily for 96 weeks (Initial Cohort), 144 weeks (Prolonged Cohort) or 48 weeks (Amendment Cohort) in combination with other antiretroviral drugs under conditions representative of standard of clinical practice for HIV-1 patients in Germany.
- Aging Participants (Type: None): HIV-1 infected participants received raltegravir 400 mg tablet orally twice daily for 144 weeks (Prolonged Cohort) or 48 weeks (Amendment Cohort) in combination with other antiretroviral drugs under conditions representative of standard of clinical practice for HIV-1 patients in Germany.~Includes newly enrolled participants ≥ 50 years of age (Amendment Cohort), plus participants from the Initial Cohort who were ≥ 50 years of age at time of recruitment and who completed 48 weeks of treatment (Prolonged Cohort).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who has been receiving a stable dose and regimen of insulin over 12 weeks before administration of investigational dug~* Patients who are under dietary management and taking therapeutic exercise for diabetes over 12 weeks before administration of investigational drug~* Patients with HbA1c of ≥7.5% and \<10.5%~* Patients who were not administered diabetes therapeutic drugs prohibited for concomitant use within 12 weeks before administration of investigational drug~Exclusion Criteria:~* Patients with type 1 diabetes mellitus, diabetes mellitus resulting from pancreatic disorder, or secondary diabetes mellitus (Cushing's syndrome, acromegaly, etc.)~* Patients with severe diabetic complications (proliferative diabetic retinopathy, stage 4 nephropathy, or serious diabetic neuropathy)~* Patients with hereditary glucose-galactose malabsorption or primary renal glucosuria~* Patients with systolic blood pressure of ≥160 mmHg or diastolic blood pressure of ≥100 mmHg~* Patients with serious renal or hepatic disease~* Patients with eGFR of \<45 mL/min/1.73 m2~* Patients who are the excessive alcohol addicts~* Patients who are pregnant, lactating and probably pregnant patients and patients who can not agree to contraception

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Canagliflozin (TA-7284) ＋insulin (Type: EXPERIMENTAL): None
- Placebo＋insulin (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-label Study of Anakinra in MPS III

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* MPS III~* ≥ 4 years of age~* Patient or parent/legal guardian is able and willing to provide informed consent. For patients 7 to 17 years of age, assent must also be provided when cognitively possible.~* If on Genistein, must have been on a stable dose for 6 months prior to enrollment~* If on melatonin or other sleep medications, must have been on stable doses for the past 3 months~Exclusion Criteria:~* Currently enrolled in another ongoing clinical treatment trial~* Previous or current treatment with anakinra, canakinumab or any other IL-1 inhibitor.~* Use of the following therapies prior to enrollment:~  * Narcotic analgesics within 24 hours prior to enrollment.~ * Tocilizumab, dapsone or mycophenolate mofetil within 3 weeks prior to enrollment.~ * Etanercept, leflunomide, thalidomide, or cyclosporine or intraarticular, intramuscular, intravenous, or oral administration of glucocorticoids within 4 weeks prior to enrollment.~ * Intravenous immunoglobulin (IVIG), adalimumab, or methotrexate within 8 weeks prior to enrollment.~ * Infliximab, 6-mercaptopurine, azathioprine, cyclophosphamide or chlorambucil within 12 weeks prior to enrollment.~ * Rituximab within 26 weeks prior to enrollment~* Live vaccines within 1 month prior to enrollment.~* Known presence or suspicion of active, chronic or recurrent serious bacterial, fungal or viral infections, including tuberculosis, HIV infection or hepatitis B or C infection.~* Clinical evidence of liver disease or liver injury as indicated by presence of abnormal liver tests:~  * AST or ALT \> 5 x ULN, or~ * AST or ALT \> 3 x ULN accompanied by elevated bilirubin \>2 x ULN.~* Presence of severe renal function impairment (estimated creatinine clearance \< 30 mL/min/1.73m2).~* Presence of neutropenia.~* History of malignancy.~* Known hypersensitivity to E coli-derived proteins, or any components of Kineret® (anakinra).~* Pregnant or lactating women.~* Current active infection;~* History of serious opportunistic infection (e.g., bacterial \[Legionella and Listeria\]; tuberculosis \[TB\]; invasive fungal infections; or viral, parasitic, and other opportunistic infections);~* Positive TB skin test, positive Quantiferon-TB Gold TB test, positive chest X-ray, or a recent exposure to TB~* Requirement for live vaccine exposure that would be expected to occur during the time frame of the study

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- treatment (Type: EXPERIMENTAL): anakinra 100 mg subcutaneous once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Short-term Structured Exercise Training Program Plus Diet Intervention in Patients With Polycystic Ovary Syndrome (PCOS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* PCOS~* Anovulation~Exclusion Criteria:~* Major Medical Condition~* Severe Obesity

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- SET-diet plus clomiphene (Type: EXPERIMENTAL): Structured exercise program plus hypocaloric diet for two months and received one-cycle of clomiphene citrate for one cycle
- Clomiphene citrate (Type: ACTIVE_COMPARATOR): One month of observation followed by one-cycle of clomiphene citrate therapy
- SET plus diet (Type: EXPERIMENTAL): Lifestyle modifications for two months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Ovarian epithelial cancer or serous peritoneal carcinoma that has relapsed after prior chemotherapy~  * Progression-free interval (from end of last treatment) of at least 6 months~* Measurable disease not required~PATIENT CHARACTERISTICS:~Age:~* Not specified~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* Not specified~Hepatic:~* Bilirubin less than 2 times normal~Renal:~* Not specified~Other:~* No sepsis~* No contraindication to chemotherapy~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* See Disease Characteristics~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Not specified

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 to 75 years (at screening for Cohort 1 and 2)~* UC confirmed on endoscopy~* Moderately to severely active UC (May score 6-12)~* Currently receiving treatment with aminosalisylate, prednisone, or budesonide~* Can be receiving azathioprine, mercaptopurine, or methotrexate, but treatment will be stopped prior to randomization~Exclusion Criteria:~* Have severe extensive colitis as evidence by:~* Physician judgment that the patient is likely to require colectomy or ileostomy within 12 weeks of baseline.~* Current or recent (within 3 months) evidence of fulminant colitis, toxic megacolon, or bowel perforation.~* Diagnosis of CD, indeterminate colitis, or the presence of fistula consistent with CD or microscopic colitis, radiation colitis, or ischemic colitis~* Clinically relevant cardiovascular conditions or other relevant diseases that could impact the implementation or interpretation of the trial, or put the patient at risk~* History of uveitis or unknown macular edema~* Pregnancy, lactation, or a positive serum β-human chorionic gonadotropin (β-hCG) measured during screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- RPC1063 (Ozanimod) (Type: EXPERIMENTAL): 1mg, daily oral administration during Induction and Maintenance periods.
- Placebo (Type: PLACEBO_COMPARATOR): Daily oral administration during Induction and Maintenance periods.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Using the Hyper-CL™ Lens (Hyper Osmotic Contact Lens) in Subjects Suffering From Corneal Edema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is over 18 years old~2. Subject with corneal edema in the visual access~3. Subject with visual acuity of 6/20 or worse (equivalent ETDRS) clinically explained by corneal edema~4. Subject understands the study requirements and the treatment procedures and provides written Informed Consent before any study-specific tests or procedures are performed.~Exclusion Criteria:~1. Subject with active Herpes keratitis~2. Subject with scarred cornea~3. Subject who is suffering from erosions and/or infections of the cornea (red eye)~4. Subject with glaucoma shunts (e.g. Ahmed valve) and or bleb~5. Subject who require chronic administration of any topical ophthalmic beside lubrication eye drops and steroids or anti glaucoma drags~6. Subject who is currently participating or have participated in an investigational study, other than this study, within the past 60 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment A-B (Type: EXPERIMENTAL): Treatment A: Hyper-CL™ lens + salt solution + antibiotics drops (7 days) Treatment B: Regular soft contact lens +salt solution+ antibiotics drops (7 days) One week (7 days) of washout without any treatment will be between treatments.
- Treatment B-A (Type: EXPERIMENTAL): Treatment A: Hyper-CL™ lens + salt solution + antibiotics drops (7 days) Treatment B: Regular soft contact lens +salt solution+ antibiotics drops (7 days) One week (7 days) of washout without any treatment will be between treatments.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* HIV positive children with elevated lipid levels~* on stable HAART for at least 3 months (defined to be on the same regimen with viral load \< 1000 for 6 months prior to baseline visit).~* Weight equal to or greater than 25kg~* Able to swallow pills or willing to learn~Exclusion Criteria:~* Patients with underlying hepatitis B or C viral infections~* Previously demonstrated clinically significant hypersensitivity (eg, Stevens-Johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of Reyataz® (atazanavir).~* Taking other medications that are highly dependent on CYP3A or UGT1A1 for clearance~  * Ergot medicines: dihydroergotamine, ergonovine, ergotamine, and methylergonovine such as Cafergot®, Migranal®, D.H.E. 45®, ergotrate maleate, Methergine®, and others (used for migraine headaches).~ * Orap® (pimozide, used for Tourette's disorder).~ * Propulsid® (cisapride, used for certain stomach problems).~ * Triazolam, also known as Halcion® (used for insomnia).~ * Midazolam, also known as Versed® (used for sedation), when taken by mouth.~ * Camptosar® (irinotecan, used for cancer).~ * Crixivan® (indinavir, used for HIV infection).~ * Cholesterol-lowering medicines Mevacor® (lovastatin) or Zocor® (simvastatin).~ * Rifampin (also known as Rimactane®, Rifadin®, Rifater®, or Rifamate®).~ * St. John's wort (Hypericum perforatum), an herbal product sold as a dietary supplement,~ * Viramune® (nevirapine, used for HIV infection).~ * Vfend® (voriconazole).~* Patients with grade 3 or higher elevations in transaminases (\> 10 X ULN)~* Women of Childbearing Potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period.~* Women who are pregnant or breastfeeding.~* Women with a positive pregnancy test.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- boosted Atazanavir (Type: EXPERIMENTAL): Boosted Atazanavir was switched for the PI or NNRTI in the patients regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Atomoxetine in the Treatment of Binge Eating Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects will meet the DSM-IV criteria for a diagnosis of binge-eating disorder for at least the last 6 months~* In addition, subjects will report at least 3 binge eating episodes per week for the last 6 months prior to randomization~Exclusion Criteria:~* Have concurrent symptoms of bulimia nervosa or anorexia nervosa~* Women who are pregnant, lactating, or of child bearing potential who are not using adequate contraceptive measures~* Patients who are displaying clinically significant suicidality or homicidality

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete